Why the study?
Do single nucleotide polymorphisms predict cardiotoxicity after anthracycline-based chemotherapy in children with cancer?
Do single nucleotide polymorphisms predict cardiotoxicity after anthracycline-based chemotherapy in children with cancer?
Answers are grounded in this paper and cite their sources.
This editorial highlights the potential importance of single nucleotide polymorphisms in predicting anthracycline-induced cardiotoxicity in childhood cancer, with possible implications for adult oncology.
Oncology brings to clinicians is the collection of content from different fields. Although I do not treat children with cancer, I make it a habit to peruse articles about pediatric oncology in the event that one of them might resonate with something of importance to my practice. Reviewing the May 1 issue of the Journal while pursuing this habit, I was rewarded by finding articles by Visscher et al 1 and Blanco et al 2 along with an accompanying editorial by Davies 3 discussing the role of single nucleotide polymorphisms in predicting cardiotoxicity after anthracycline-based chemotherapy for childhood cancer.
No takes yet. Share an insight, caveat, or question.
Carl D. Atkins (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: